THERAKOS® CELLEX® Photopheresis System

THERAKOS® CELLEX® Photopheresis System

THERAKOS® CELLEX® delivers a fully integrated, automated extracorporeal photopheresis (ECP) system, providing superior efficiency, safety, and patient outcomes.

Key advantages:

  • Faster treatment times(1):
    • Single-needle mode: 105 mins/Treatment
    • Double-needle mode: 75 mins/Treatment
  • Only Online, integrated device to be approved by both FDA and EU certified.
  • Workday Limitation: Based on a 7.5-hour workday (450 minutes)(2), integrated systems triple patient throughput, maximizing efficiency and bed utilization in clinical settings.
  • Compact and integrated system that enhances mobility.
  • Single machine performs cell collection, ECP treatment and reinfusion of treated blood back to the patient, thus reducing the hidden cost.
  1. Data on file. Ref-01420. Mallinckrodt Pharmaceuticals.
  2. Azar N, Leblond V, Ouzegdouh M, Button P. A transition from using multi-step procedures to a fully integrated system for performing extracorporeal photopheresis: A comparison of costs and efficiencies. J Clin Apher. 6 2017 Dec;32(6):474-478. doi: 10.1002/jca.21542. Epub 2017 Apr 17. PMID: 28419561; PMCID: PMC5724655

Value Proposition

Cellex – a completely connected, inline device which requires only 90 minutes for a whole treatment as against the 240 to 270 minutes required by other machines.

100 Reduced Hospital Stays
500 Improved Transplant Outcomes
4200 Smiling Customer

How the THERAKOS® CELLEX® System Works:

  1. Blood Collection:
    • The patient’s blood is drawn, and the white blood cells (including T cells) are separated from the rest of the blood using centrifugation.
  2. Photoactivation:
    • A photosensitizing agent, such as 8-methoxypsoralen (8-MOP), is introduced. This agent makes T cells sensitive to ultraviolet A (UVA) light.
    • The separated white blood cells are then exposed to UVA light, which damages the DNA of the treated cells, rendering them apoptotic (programmed cell death).
  3. Reinfusion:
    • The treated white blood cells are reinfused back into the patient, where they induce an immunomodulatory effect by stimulating regulatory T cells (Tregs) and reducing inflammation or abnormal immune responses.

With faster treatment times, continuous operation, and advanced customization, Cellex reduces manual errors, increases patient throughput, and ensures precision for personalized care setting the standard for modern photopheresis systems.

Our THERAKOS® CELLEX® Customers

Our customers are the pillars of our strength and motivation to strive for a better tomorrow.

Dr. Swaminathan

Utilized machine on more than 10 marginal organs (both liver and kidney). Vitasmart benefits lots of patients by transplanting them with Marginal organs which otherwise would have been discarded

Dr. Prabhu Kanchi

There are very less incidences of DGF, PNF and low rejection rates compared to static cold storage

Dr. Elankumaran K

Extended criteria organs were allocated to the patients benefited with shorter hospital stay

John M Kenedy

Far far away, behind the word mountains, far from the countries Vokalia and Consonantia, there live the blind texts.

Arjun Pandit

Even the all-powerful Pointing has no control about the blind texts it is an almost unorthographic life One day however a small line of blind text by the name of Lorem Ipsum decided to leave for the far World of Grammar.

Global Partnerships

Latest Blogs

Our latest published articles

Interested to know more?

To learn more about Duraent's innovative organ preservation solutions and transplant technologies, contact us. Discover how we empower medical professionals to deliver life-saving results through groundbreaking products like VitaSmart™ and Belzer UW® Cold Storage Solution.

Request a Demo